0:00 Welcome back everybody. Type one diabetic warriors. My name is Jim and today we've got another big announcement from Sana Biotechnology. You may remember their program is called SC 451. Yeah, I got that right. SC 451. That is their technology to disguise, make transplanted cells invisible from the attack system known as your immune system. We have a big announcement today because there is a very world renowned, exciting organization called the Mayo Clinic who wants to get in bed with them, so to speak, and pursue this in new trials, hopefully starting this year. We've got the whole story for
0:47 you. We're going to unwrap it for you right now. Thanks for joining us today. If you like our channel's content, feel free to hit the link in the description and buy us a coffee. We appreciate all our viewers who support our channel. Now onto our video. Mayo Clinic just backed a no-drug T1D cure trial starting soon. Something big just happened in the race for a type 1 diabetes cure. And this time, it's not just hype, because a small biotech company just partnered with one of the most respected medical institutions in the world, the Mayo Clinic, to test a therapy that could make insulin-producing cells completely invisible to the immune system. And when this news dropped, the stock jumped 22% almost instantly. That's not normal. That means
1:34 something just got real. Let's break this down because this story hits three things that actually matter. Serious money is paying attention and human trials are starting soon. The company is Sana Biotechnology and their lead type one diabetes program is called SC-451. Now, at first glance, this might sound like everything else we've covered, but this is different. They're not trying to stop the immune system anymore. They're trying to outsmart it. Every potential cure runs into the same wall. The immune system destroys the new insulin-producing cells. So most approaches try to suppress the immune system. But that comes with risks. Lifelong drugs. And for a lot of people, that's just not a great trade. Sana is flipping that idea completely. Instead of stopping the attack, they're building cells the immune
2:23 system can't see. SC451 uses genetically engineered islet cells designed to avoid detection so they can survive and produce insulin without the need for anti-rejection drugs. No immunosuppression. One-time treatment. That's the goal. Now here's where this story really changes. They partnered with the Mayo Clinic. And that matters more than most people realize. Mayo Clinic is one of the top clinical research institutions in the world. don't attach their name to hype so when they step in it tells us this is past serious review there's real infrastructure behind it and this is moving toward real patient testing this is no longer just a lab idea this is becoming real then you look at the market reaction sauna's stock jumped about 22
3:10 percent in pre-market trading that's not random that's institutional money reacting that's analysts and funds saying okay this just got more legitimate And when you combine that with Mayo Clinic stepping in, people are paying attention for a reason. Here's the next big step. Human trials are expected to begin soon. That's huge because now we move from theory to reality. Phase one is about safety. Do the cells survive? Do they avoid the immune system? Do they produce insulin consistently? We're not talking about a cure tomorrow, but we are talking about the first real test of this idea in humans. Now we've got to stay grounded. There are still big unknowns. How long will these cells last? Can the immune system eventually recognize them? Can this be
3:56 scaled to large numbers of people? We've seen promising therapies before that didn't pan out. So this is early, but it's meaningful early. What makes this moment different is the combination, a new strategy, a major institution stepping in, serious money reacting and human trials are on deck. Hopefully the first phase will start in 2026. So the question is, did we just take a real step toward a world without insulin injections? Or is this another idea that won't make it through? We're about to find out, and I'll be tracking this every step of the way. From this channel's perspective, that is a great way to start this journey. SC451, we've been talking about it for two or three years. So they have refined it, they
4:44 have gone through the theory, the preclinical, you know, studies with mice. And now we have the possibility of a no drug T1D cure. And to just to sweeten this story up, the fact that Mayo Clinic, who gets to review many, many different therapies, and they tell, they, I think they turned down most of them, but not this one. They think that there's something here and there's some institutional money from Wall Street behind this too. So those are all the ingredients for a possible, you know, home run. It's not gonna be ready tomorrow. It will start trials probably in 2026. So we're almost halfway through the year. So that's all good news.
5:31 We will follow it as always right here on all things type one diabetes, type one diabetic warriors, and you all take care of yourself and we'll talk again here real soon.
